Radiation Protection Drug Shows Promise In Animal Tests
Scientists in the US have developed a drug that protected laboratory mice and monkeys from radiation damage and may one heyday be used to protect people
from the side effects of dispersal used in medical procedures such as cancer treatments, and even the effects of nuclear weapons.
A inquiry describing the laboratory findings is published today, 11th April, in the early online issue of Subject and is the work of investigators from
the Roswell Park Cancer Institute and Cleveland BioLabs, Inc, both in Buffalo, Revitalized York; supplementary the Lerner Fact-finding Institute at the Cleveland Clinic in Ohio,
and the Burnham Institute for Medical Fact-finding in La Jolla, California.
Exposure to dispersal causes cells to commit suicide by triggering programmed chamber decease or apoptosis. However, tumour cells have a course of action of stopping
apoptosis, which is why cancer cells proliferate.
Cleveland BioLabs developed an experimental sedate called CBLB502 to prompt the signalling mechanism Euphemistic pre-owned by tumour cells to hold in check apoptosis to see if it
could protect healthy cells from radiation harm.
CBLB502 is a polypeptide derived from the whip like tails of the Salmonella bacterium and it binds to a cubicle receptor called TLR5 to trigger appropriate
apoptosis-suppressing signal.
In the course of this study, the scientists gave laboratory mice a single injection of CBLB502 and then exposed them to a lethal amount body dose of emanation.
The drug protected the mice against the effects of radiation on organs of the digestive tract and in blood apartment producing bone marrow (protected against “gastrointestinal and
hematopoietic acute radiation syndromes”) and improved their survival.
Other mice that were injected after being irradiated also survived longer, but only at diminish doses of radiation.
Similar effects were demonstrated in rhesus monkeys, with 90 per cent of lethally irradiated monkeys surviving after three weeks compared with 20 per cent of
the controls.
The scientists concluded that:
“TLR5 agonists could potentially renovate the health-giving ratio of cancer radiotherapy and be of assistance as biological protectants in radiation emergencies.”
Pattern week, on 3rd April, the US Department of Defense awarded Cleveland BioLabs an 8.9 million dollar preliminary contract
to show CBLB502 as a “Medical Emanation Countermeasure to treat radiation injury following revelation to radiation from atomic or radiological
weapons.”
The corporation is developing another series of drugs called CBLB600, which stimulate the immune system. These could be cast-off with CBLB502 to protect against
diffusion injure (which also affects the unsusceptible system) or on its own to reduce the side effects of chemotherapy.
They are also exploring the exigency execrate of CBLB600 as a in work to produce stem cells after discovering that the add to increases numbers of hematopoietic stem cells
(HSC) in both the bone marrow and peripheral blood.
“An Agonist of Toll-In the mood for Receptor 5 Has Radioprotective Activity in Mouse and Primate Models.”
Lyudmila G. Burdelya, Vadim I. Krivokrysenko, Thomas C. Tallant, Evguenia Strom, Anatoly S. Gleiberman, Damodar Gupta, Oleg V. Kurnasov, Farrel L. Fort,
Andrei L. Osterman, Joseph A. DiDonato, Elena Feinstein, and Andrei V. Gudkov.
Science 11 April 2008, Vol. 320. no. 5873, pp. 226 - 230.
DOI: 10.1126/science.1154986.
Click here as regards Abstract.
Sources: Journal Ideational, Cleveland BioLabs.
Written by: Catharine Paddock, PhD
Copyright: Medical News Today
Not to be reproduced without permission of Medical Dirt Today